FP7Individual fellowship2012–2013

ProteasiX · A novel bioinformatics’ platform to identify key proteasic pathways involved in kidney diseases

FP7 — People (Marie Curie Actions)

Duration
2012-05-01 → 2013-04-30
EU contribution
€104,517
Participants
1
Scheme
MC-IEF

Lines connect the coordinator with its partners.

Results in brief

A novel bioinformatics’ platform to identify key proteasic pathways involved in kidney diseases

Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation Proteases are involved in numerous pathophysiological processes and produce peptides as evidence of their activity. The human genome encodes more than 500 proteases, many of which are orthologous, indicating the significance of this class of enzymes to biological processes. Modifications of protease activity have been associated with many pathologies including cardiovascular, inflammatory and fibrotic diseases, cancer, or neurological disorders. Understanding the protease network in health and disease represents a major research question highly relevant for pathophysiology, biomarker discovery and drug development. Body fluids (e.g. serum, urine, cerebrospinal fluid) contain thousands of protein peptides; a substantial number of disease-associated peptides have been described for a variety of disorders such as kidney, cardiovascular, autoimmune, infectious diseases and certain types of cancer. This quantity of accumulated data is in direct contrast to the (lack of) knowledge about the mechanisms leading to the generation of these peptides, which may hold the key to linking the observed biomarkers to pathophysiology. As a first step in this direction we examined links between naturally occurring peptides and the proteases that may be responsible for their generation. The underlying hypothesis is that changes in protease activity may be linked to disease pathophysiology in a more direct way than the generated peptide itself. Information about proteases and their cleavage sites is, however, scattered across publications and databases, different formats, and not always suitable for automatic computed searches. TopFIND, the MEROPS peptidase database, the CutDB database are large information resources for proteolytic events, documenting proteases from different organisms, along with their experimentally identified or predicted substrates and observed cleavage site sequences. Although useful, these databases still present several limitations. Proteases and substrates are sometimes defined using obsolete identifiers, or textual descriptions not corresponding to annotation standards, while most proteomics results are annotated using stable SWISS-PROT curated identifiers. Moreover, none of the resources allow for batch searches and cleavage sites must be manually queried one by one. Finally, these different databases are either protease-, cleavage site- or substrate-centric, and do not permit automatic cleavage site retrieval for peptide sequence input. As a result, querying has to be performed manually, including initial sequence alignment with the full-length protein to identify N- and C-term cleavage sites, and in some cases also requires specific knowledge of protein names and representation. To address this we developed Proteasix (www.proteasix.org), an open-source peptide-centric tool that can be used in an automatic and large-scale fashion to predict in silico the proteases involved in native peptide generation. The main component of Proteasix is the underlying curated cleavage site database, containing 3500 entries about human protease/cleavage site combinations. On top of this database, we built a bioinformatics tool, Proteasix, which allows cleavage site retrieval and protease associations from a list of peptides. To establish the proof of concept of the approach, we used a list of 1388 peptides identified from human urine samples, and compared the prediction to the analysis of 1003 randomly generated cleavage sites. Metalloprotease activity was predominantly involved in urinary peptide generation and more particularly to peptides associated with extracellular matrix remodelling, compared to proteins from other origins. In comparison, random cleavage sites returned almost no results, highlighting the specificity of the prediction. This project provides a unique tool that can facilitate linking of identified protein peptides to predicted protease activity, and therefore into presumed mechanisms of disease. Experiments are needed to confirm the in silico hypotheses. We believe that this tool will be of great interest to understand and define the protease networks in health and disease, representing a major clinical objective in terms of pathophysiology, biomarker discovery and drug development for many diseases such as cardiovascular, inflammatory and fibrotic diseases, cancer, or neurological disorders.

Data: CORDIS, © European Union

Project objective

The aim of this project is to develop a new bioinformatics’ platform that will for the first time allow the identification of the key proteasic pathways involved in the development of kidney disease in an automatic and systematic way. Proteases generate peptides through cleavage of specific sites, present on given protein substrates. Interestingly, recent clinical studies have led to the identification of diagnostic and prognostic peptide biomarkers of a variety of nephropathies. The platform will thus contain a database grouping all these clinically relevant peptides and will automatically retrieve the enzymes involved in their generation by analyzing the sites that have been processed. To achieve this, the proposed work will use specific knowledge of the kidney pathophysiology in combination with state-of-the-art technologies in the bioinformatics’ field. The novelty of this project relies on: 1) automation of the process on large amount of data (gain of time); and 2) focus on enzymatic activity that will complement more classically used analyses of gene or protein expression (gain of knowledge). The disease-associated proteasic pathways identified in-silico will later be validated in a life-science lab and should lead at the long term to an improved understanding of the development of kidney diseases

Original text from CORDIS.

Participants

Links

Data: CORDIS, © European Union